Windlas Biotech Investor Presentation: Q4 & FY26 Results
Windlas Biotech reported its highest-ever annual revenue of ₹904 Cr for FY26, a 19% YoY increase. Q4 FY26 revenue grew 18% YoY to ₹238 Cr. The company achieved an EPS of ₹31.60 and proposed a dividend of ₹13 Cr (₹6.30 per share). Key verticals like CDMO, Trade Generics, and Exports showed strong growth. Plant-6 is set for commercialization by H1 FY27.
The announcement details strong financial results, including record revenue and EPS, growth in key business segments, and progress on manufacturing facilities, all of which are material information for investors and indicate significant company performance.
The company reported record revenues, strong financial performance with increased EPS, and growth across key business verticals. Strategic investments in manufacturing facilities and a proposed dividend further contribute to a positive sentiment.
Windlas Biotech Limited has released its Investor Presentation for Q4 and FY26, showcasing a strong financial performance and strategic progress.
The company reported its highest-ever annual revenue of ₹904 Cr for FY26, an 19% year-on-year increase. Q4 FY26 revenue also saw significant growth, up 18% YoY to ₹238 Cr, marking the 13th consecutive quarter of record revenue. This consistent growth underscores the company's focus on scalability, durability, and profitability.
Financially, FY26 saw the highest post-listing Earnings Per Share (EPS) of ₹31.60. Adjusted EBITDA stood at ₹121 Cr (13.4% margin) and Adjusted PAT was ₹83 Cr (9.2% margin), excluding non-cash ESOP costs. Reported EBITDA for FY26 grew 11% to ₹105 Cr, with reported PAT rising 9% to ₹66 Cr.
Key business verticals demonstrated robust growth. The Generic Formulations CDMO segment achieved ₹664 Cr in FY26, a 20% YoY increase. The Trade Generics & Institutional vertical grew 13% to ₹195 Cr, and the Exports vertical surged by 40% to ₹46 Cr.
Strategic investments continue to drive growth. Plant-4 and Plant-5 (Injectable Facility) received GMP certification from the Philippines. Plant-6 has achieved mechanical completion and is on track for commercialization by H1 FY27. The company also completed a ₹47 Cr share buyback, excluding promoter participation, and has proposed a dividend of ₹13 Cr (₹6.30 per share) for FY26.
Looking ahead, Windlas Biotech aims to enhance long-term shareholder value through client base diversification, operational efficiencies, talent retention, and expansion of dosage forms. The company maintains a strong net liquidity position of ₹251 Cr and is net debt-free.
What to do with a filing like this
Windlas Biotech Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Windlas Biotech Limited. Read the original for the full detail.